Unlearn is a private AI company that creates digital twins of clinical trial participants to make trials smaller, faster, and more efficient. Its technology is used in drug development to model patient outcomes and improve study design.
Access to pre-IPO shares is available to accredited investors through UpMarket.
Latest Price
$900M
Series B, Jan 2024, Perplexity
UpMarket Estimate
$983M
Based on UpMarket valuation model
Previous Price
$100M
Series A May 2020
How to Invest in Unlearn Through UpMarket
Unlearn shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Step 01
Verify accredited investor status
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Step 02
Create an UpMarket account
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Step 03
Review available Unlearn offerings
Full offering memoranda and risk disclosures provided before any commitment is required.
Step 04
Complete subscription documents
Review and sign subscription agreement. All documents handled digitally through the platform.
Step 05
Fund your investment
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
Jan 2024
Series B
$900M
May 2020
Series A
$100M
Why Investors Are Watching Unlearn
Growth Signal
Unlearn raised $50M Series C to scale digital twins
Unlearn announced a $50 million Series C led by Altimeter Capital, with returning investors including Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. The company said the round would support workforce growth, data expansion, and additional R&D and engineering investment.
Competitive Moat
First ML platform for patient digital twins in trials
Unlearn describes itself as the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies. Its core product, TwinRCTs, is designed to optimize clinical research by modeling treatment effects on trial participants.
Market Opportunity
Clinical-trial AI company has raised over $130M total
Unlearn has raised more than $130 million since 2017, including a $50 million Series B in April 2022 and a $50 million Series C in February 2024. The repeated funding rounds suggest investor conviction in the market for AI tools that improve clinical trial efficiency.
Interested in Unlearn stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, Unlearn is a private company and does not trade on any public stock exchange. Accredited investors can access Unlearn shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
Unlearn does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in Unlearn shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.
Pre-IPO investments carry significant risks. Unlearn shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
Unlearn creates digital twins of clinical trial participants to make drug development trials smaller, faster, and more efficient, and is valued at $983M after its $50M Series C to scale the platform — accredited investors can access Unlearn stock through UpMarket.